CBL (Chemical and Biopharmaceutical Laboratories) is a global peptide manufacturing technology company founded in 1990 by Prof. Dr. Kleomenis Barlos, to provide the industry with novel chemistries in key areas of solid phase peptide and organic synthesis. Over the past 19 years, CBL has developed a reputation as a premier supplier in the peptide industry. CBL strives to maintain a reputation for excellence by expanding capabilities and developing innovative technology.
CBL is one of the largest peptide material suppliers in the world, offering peptide starting materials, peptide intermediates, and industrial and commercial-scale manufacturing of proprietary and generic GMP and non-GMP peptides. With facilities that accommodate programs from the gram to ton range, CBL develops partnerships that grow from the laboratory scale to commercial production.
CBL operates out of four laboratory and manufacturing buildings, spanning over 10,000 square meters. Development of highly automated, efficient facilities enables CBL to operate from the gram to ton scale, both for solid and solution phase syntheses. CBL’s state-of-the-art equipment and facilities have been designed from the ground up for peptide synthesis, setting new standards for GMP synthesis at both the small and large scale.
CBL has been a leader in peptide technology since the founding of the company when Prof. Kleomenis Barlos discovered and developed the trityl resins. Today, CBL has been recognized for its involvement in the synthesis and supply of key materials for several complex peptides including Roche’s HIV-treatment, enfuvirtide, GLP-1’s, Relaxins and other insulin-like peptides. CBL’s scientific expertise is recognized for delivering innovative solutions for the synthesis of some of the most complex peptides and proteins.